Unibest

Pharmaceutical intermediates

Lenvatinib Mesilate Intermediates

4 pharmaceutical intermediates for Lenvatinib Mesilate. Indication: Renal cell carcinoma; Endometrial carcinoma; Hepatocellular carcinoma; Thyroid cancer.

提交项目All intermediates

About Lenvatinib Mesilate

Originator
Eisai Inc
Indication
Renal cell carcinoma; Endometrial carcinoma; Hepatocellular carcinoma; Thyroid cancer
Approved Date
02/13/2015
DS/DP
10/24/2025

Available intermediates

4 intermediates currently listed for Lenvatinib Mesilate. Request specifications, documentation or a quotation for any item below.

Lenvatinib Mesilate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
4-Chloro-7-methoxyquinoline -6-carboxylic acid methyl ester205448-66-4//
4-Chloro-7-methoxyquinoline -6-carboxamide417721-36-9//
N-(2-Chloro-4-hydroxyphenyl)-N'-cyclopropyl-urea796848-79-8//
4-Amino-3-chlorophenol17609-80-2//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lenvatinib Mesilate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →